Additionally, strong evidence from several studies has revealed that blocking PD-1/PD-L1 by neutralizing PD-1 or PD-L1 can abrogate the immune evasion of tumor cells and activate CD8+ T cells [30–32], indicating that antibodies against PD-1 and PD-L1 are effective clinical immunotherapies for cancers [33–35]. The gene discussed is CD8A; the disease is cancer.